Adding a probiotic helped H. pylori treatment succeed, with fewer side effects

Helicobacter pylori is a common stomach infection, and clearing it means taking a course of combined medicines that does not always succeed and often brings unpleasant side effects. Anything that raises the odds of success or makes the course easier to tolerate is therefore worth testing properly. Probiotics from the Lactobacillus family have been proposed as an add-on because they may modulate the gut microbiota and immune responses during treatment. Individual trials have pointed in different directions, so this review set out to pool them and settle whether the addition genuinely helps.

The authors searched PubMed, Embase and the Cochrane Library up to August 2026 for randomised trials comparing standard Helicobacter pylori eradication therapy with and without a Lactobacillus supplement. The primary outcome was eradication success and the secondary outcome was adverse events, pooled using a random effects model. They also estimated the number needed to treat and ran subgroup analyses by antibiotic regimen, treatment duration, Lactobacillus strain, dosage, period of use, formulation, geographical region and age range. In total 32 trials covering 4,010 patients met the criteria, and the review was registered in advance on PROSPERO.

Adding Lactobacillus improved eradication success with a relative risk of 1.10, which works out at a 10% relative increase and a number needed to treat of 13, meaning roughly one extra person cured for every 13 given the probiotic. Adverse events fell too, with a relative risk of 0.70, a 30% relative reduction. The subgroup analyses added important texture: the eradication benefit was seen only with triple therapy regimens, not with other antibiotic combinations. The reduction in adverse events, meanwhile, appeared only among adults.

Probiotic add-ons to eradication therapy have been studied for years with mixed individual results, and this pooling of 32 trials gives the Lactobacillus approach its clearest quantitative backing yet. The restriction of benefit to triple therapy is a genuine complication, since it suggests the probiotic may not help with every regimen a clinician might prescribe. The review also leaves open which strains, doses and timings work best, questions its own subgroup analyses could only begin to address. Larger head-to-head comparisons of strains and regimens would be needed to answer them.

If you are ever prescribed treatment to clear Helicobacter pylori, this is worth knowing: in pooled trials, taking a Lactobacillus probiotic alongside the standard course was linked to better odds of success and noticeably fewer side effects. The effect on success was modest, about one extra cure for every 13 people treated, so it is a helpful nudge rather than a transformation. The pattern of benefit also depended on the regimen and applied to adults, so the detail of a given prescription matters. That makes this context to bring into a conversation about treatment rather than a plan to act on alone.